High Times
Home > Boards > US OTC > Medical - Drugs >

Generex Biotechnology Corp. (GNBT)

Add GNBT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/16/2018 9:41:03 PM - Followers: 200 - Board type: Free - Posts Today: 0


Welcome to Generex

Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.

Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information about Antigen Express visit www.antigenexpress.com.

Mission Statement

Our mission is to develop innovative drug delivery technologies and drugs that will improve the quality
of life for people who suffer from disease.

Management Team

Mark Fletcher
President & Chief Executive Officer

Mark Fletcher, Esq. Mr. Fletcher was appointed as President and Chief Executive Officer in March 2011 and has served and continues to serve as Secretary since September 2010 and as General Counsel since April 2003.  Mr. Fletcher was appointed as Interim President/Chief Executive Officer and Secretary in September 2010.  In April 2003, he took the position of Executive Vice President and General Counsel with Generex.  From October 2001 to March 2003, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a leading Toronto law firm. From March 1993 to September 2001, Mr. Fletcher was a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto. Mr. Fletcher received his LL.B. from the University of Western Ontario in 1989 and was admitted to the Ontario Bar in 1991.  The Board believes that Mr. Fletcher's wide-ranging legal knowledge and extensive experience as a practicing lawyer, combined with his managerial skills and business acumen and judgment, provide our Board with valuable legal and operational expertise and leadership skills.
Dr. David Brusegard Ph.D
Chief Operating Officer (COO)

Dr. Brusegard has a breadth of experience in several fields of endeavour including, medical record design, health informatics, health insurance, digital mapping, database design, global positioning systems applications, business management and strategic planning. He was a senior economist at Statistics Canada for a decade, an adjunct professor at the University of Toronto and taught information ethics and information law at Ryerson University. He has consulted internationally on information management for the World Bank as well as major consumer packaged goods companies, hospitals, municipalities, and all levels of government. Recent positions of note include; Vice President, Analytics for ICOM Communication and Information, President of Geographic Decision Support Systems, CEO, Tristar Software, and CEO of the Pentius Group (a 5 company health insurance and managed care portfolio).

Dr. Brusegard's graduate work was carried out at The University of North Carolina at Chapel Hill, and the University of Calgary from which he holds a Ph.D. Phil.

Stephen Fellows
Acting Chief Financial Officer (CFO)

Mr. Fellows has over 20 years of experience in financial management and accounting reporting for both public and private companies, including debt and equity financings. As Acting Chief Financial Officer, he is instrumental in helping to direct and oversee Company financial and accounting procedures while providing strategic planning for creating future revenue streams including joint ventures and licensing arrangements for the Company's current portfolio of products as well as its product development pipeline.

Prior to joining Generex, Mr. Fellows spent almost four years at Sona Mobile Holdings Corporation, a publicly held software company which developed software applications for mobile devices, where he served as Chief Financial Officer. Mr. Fellows joined Sona Mobile from 3Com Corporation, where he was the Director of Finance of the corporate accounting group in Marlborough, MA. Prior to that, Mr. Fellows spent five years as the Director of Finance & Operations of 3Com's Canadian subsidiary. Mr. Fellows joined 3Com from Pennzoil Corporation where he spent time in the international mergers and acquisitions group in Houston, Texas, as well as four years as Controller for Pennzoil Canada.

Mr. Fellows holds a Bachelor of Business Administration degree from Wilfrid Laurier University in Waterloo, Ontario, Canada and earned his Chartered Accountants designation while articling with Arthur Andersen & Company in Toronto.

Dr. Eric von Hofe, Ph.D.
Vice-President of Generex and President of Antigen Express

Dr. Eric von Hofe, has been President of Antigen Express since April 2005. He joined Antigen in November 2003 as Vice President of Technology Development of Antigen. He has extensive experience with technology development projects, including his previous positions at Millennium Pharmaceuticals first as Program Director for Target Validation and later as Director of Programs & Operations, Discovery Research. Prior to that, Dr. von Hofe was Director, New Targets at Hybridon, Inc., where he coordinated in-house and collaborative research that critically validated gene targets for novel antisense medicines. Dr. von Hofe also held the position of Assistant Professor of Pharmacology at the University of Massachusetts Medical School, where he received a National Cancer Institute Career Development Award for defining mechanisms by which alkylating carcinogens create cancers. He received his Ph.D. from the University of Southern California in Experimental Pathology and was a postdoctoral fellow at both the University of Zurich and Harvard School of Public Health. His work has been published in forty-seven articles in peer-reviewed journals, and he has been an inventor on four patents.

Dr. Gerald Bernstein, M.D.
VP Medical Affairs

Gerald Bernstein,M.D., F.A.C.P. Graduated from Dartmouth College and Tufts University School of medicine. He is board certified in internal medicine (1966) and endocrinology and metabolism (1973). He entered practice in 1966 after completing a research fellowship. Dr. bernstein is an associate clinical professor at Albert Einstein College of Medicine in New York. He is an attending physician at Beth Israel Medical Center, Lenox Hill Hospital (1974) and Montefiore Medical Center (1966). He served on the National Board of Directors of the American Diabetes Association, its research foundation and many national committees. He was on the editorial board of the publication "Clinical Diabetes". He has been president of the New York Downstate affiliate of the American Diabetes Association. He is the author of many papers, clinical and scientific and the book "If it runs in your family: Diabetes Mellitus, Reducing your Risk". Dr. Bernstein is a past president of the American Diabetes Association and was Director of the Beth Israel Health Care Systems Diabetes Management Program. He is currently Director of the Diabetes Management Program of The Friedman Diabetes Institute at Beth Israel Hospital in New York. He has served as Vice President for Medical Affairs at Generex Biotechnology Corp. Since 2001.

Dr. Jaime Davidson, M.D.
Medical Director

Dr. Jaime Davidson, MD., F.A.C.P. was appointed a consultant Medical Director for Generex in July, 2006. Dr. Davidson is the President of Endocrine and Diabetes Associates of Texas, based at the Medical City Dallas Hospital complex, and a Clinical Associate Professor of Internal Medicine at University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Davidson chaired the Diabetes Consensus Guidelines for the American College of Endocrinology and serves as Director of the Annual Intensive Diabetes, Endocrinology and Metabolic Diseases Course for the University of Southern California Keck School of Medicine. He serves as a council member for the Texas Department of Health Services, appointed by Texas Governor Rick Perry. In 2006 Dr. Davidson was distinguished by the American Association of Clinical Endocrinologists with an award for his contributions to the improvement of endocrine health for under-served populations, and by the American Diabetes Association with the Harold Rifkin MD award for his international contributions in the diabetes field. In the past, he has held positions with the National Diabetes Advisory Board, the National Institutes of Health, the Centers for Disease Control, the Institute of Medicine, and the boards of directors of the American Diabetes Association, the American Association of Clinical Endocrinologists, and the American College of Endocrinology. He served in higher education for a six year term as a Regent of Midwestern State University in Texas appointed by then Governor George W. Bush. He has also served in the President's Council for Fitness and Sports, chaired the Texas Diabetes Council of the Texas Department of Health for several years where he instituted the Texas Diabetes Algorithm, and under his guidance the Texas Diabetes Institute was established with the University of Texas Health Science Center in San Antonio, Texas. Dr. Davidson's experience in clinical pharmacology began with a Clinical Pharmacology Fellowship at Lilly Laboratories for Clinical Research and it continued with multiple clinical trials. In addition, he was an advisor to the Food and Drug Administration (FDA) on the Endocrinology and Metabolism Advisory Board. Dr. Davidson's Internal Medicine training was completed at Scott and White Hospital (now known as Texas A&M University) and his Endocrinology training at University Of Indiana.


Generex is currently conducting pre-clinical and human clinical trials using its proprietary technology platforms in the areas of diabetes, pain management and cancers.




Generex has two platform technologies in the area of drug delivery and immunomedicines.

Drug Delivery - RapidMist™:

Comprised of a proprietary device & pharmaceutical agents in an aerosolized liquid formulation.

Delivered through the buccal mucosa (inner cheek of mouth) and NOT THE LUNGS.

Applicable to most proteins and peptides.


Antigen Express technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.


Antigen Express

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for active immunotherapy as well as disease prevention.

In contrast to traditional therapies, the goal of active immunotherapy is to amplify the patients' ability to fight specific disease rather than targeting the diseased tissue or pathogenic agent directly. The novel technologies being developed at Antigen Express allows for robust and antigen-specific stimulation of CD4+ T cells, a cell type critical in the recognition of pathogens and modulation of the immune response.

Antigen Express is developing these technologies for application to the treatment of cancer, infectious diseases, and other serious diseases. Our most advanced vaccine utilizes a self-potentiating peptide as an off-the-shelf product for active immunotherapy of breast and prostate cancer

To find out more on Antigen Express please go to www.antigenexpress.com.


Eric von Hofe, PhD

Dr. von Hofe joined Antigen Express in November of 2003. Prior to this time he held two positions at Millennium Pharmaceuticals; first as Program Director for Target Validation, where he presided over technology development efforts for Aventis and Cereon, and second as Director of Programs and Operations, Discovery Research. He received his Ph.D. from the University of Southern California and was a postdoctoral fellow at the University Hospital of Zurich and Harvard. From 1989 to 1992 he was Assistant Professor of Pharmacology at the University of Massachusetts Medical School.

Robert E. Humphreys, MD, PhD
Founder (retired)

Dr. Humphreys was the Chief Scientific Officer of Antigen Express from it's inception, and at the time of his retirement held the position of Executive Vice President. Prior to joining Antigen Express, he was Professor of Pharmacology and Medicine, and interim Chair of Pharmacology at the University of Massachusetts Medical School. He received his BS, PhD and MD at Yale, and served in the US Navy at the US Naval Hospital and Naval Medical Research Institute in Bethesda. He was a postdoctoral fellow of Dr. Jack Strominger at Harvard. He has published over 140 peer-reviewed papers and has served 10 years on NIH study sections.

Catherine Blackwell
Business Operations Manager

Catherine Blackwell became a member of Antigen Express in January of 2004. She is responsible for managing the business operations of Antigen Express along with grants management and human resources. Preceding her position at Antigen Express, she was the project coordinator and accounting manager for Cyagra Incorporated, a biotechnology company specializing in agricultural cloning. She received her Bachelors degree in Veterinary Science in 1987 from the University of Massachusetts and a Masters degree in Education in 1991 from Anna Maria College.



Generex is dedicated to the research, development and commercialization of drugs delivery via the buccal mucosa. Generex seeks to out-license its RapidMist™ product programs and identify in-licensing opportunities and acquisitions in the areas of diabetes, drug delivery, cancer, H5 avian influenza, HIV, generic and branded prescription drugs, 505(b)2 product candidates, and late stage development opportunities.

Here are some of the companies we have partnered with; Please click on logos the get the details.

Medipharma S.A.

From its beginnings in 1982 Medipharma S.A. (www.medipharma.com.ar) is dedicated to the development and pharmaceutical product elaboration for human consumption, taking quality as the basic premise. Thus its Productive facilities, Laboratory of Quality and Microbiological Control have evolved continuously according to the more outpost norms from quality assurance (GMP - Good Practices of Manufacture), always with constant efforts in Investigation and Development. Several of our products count on studies of bioavailability approved by the Argentine sanitary authorities. This action of almost three decades, has allowed us to enter like suppliers of all the great welfare centers of the country and more recently to strengthen in the ethical market. The laboratory of Quality Control counts on equipment that allows us to compliment with the international norms as far as analytical and microbiological controls. Our productive areas count on equipment and personnel that have distinguished us in the medicine production of high risk (low product concentration with dangerous pharmacologic limits, for example digoxin) Complimenting GMP 2002, our company has all its productive and control equipment qualificated as well as all its productive and cleaning processes validated (reviewed and approved by our national authorities in 2005). We have also signed agreements of Investigation and Development with the C.O.N.I.C.E.T. and the National University of La Plata, for the obtaining of active principles of last generation.  One of the research groups working on a calcium supplement directed to stimulate the passive absorption, independent of age and hormonal status of the patient, stimulating the gastrointestinal absorption of calcium through the formation of a micelle in situ transportable via passively into the bloodstream, independent of vitamin D and / or estrogen intake. This research is oriented towards the prevention and / or treatment of osteoporosis.  The other research group studies a new derivative of valproic acid molecule which by its molecular structure allows cross the blood-brain barrier. This new molecule will allow the health professional to manage a dosage regimen involving the administration to patients of up to 100 times lower dose of valproic acid, than those used with existing molecules, reducing the adverse effects associated with toxicity of the same.

Sanofi-aventis (www.sanofi-aventis.com), a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


Merck Serono

Merck Mexico (www.merckserono.com) was founded in 1930 as one of the first pharmaceutical producers in Mexico. Today, with close to 1,035 employees, Merck, S.A. de C.V. manufactures and sells a great variety of products for the treatment pain, diabetes, thyroid problems, colds, growth hormone, multiple sclerosis and cancer, among other diseases. In its chemical area, Merck has specialty pigments and active ingredients for the cosmetics industry.

Dong Sung Pharmaceuticals

Dong Sung Pharmaceuticals (www.dongsung-pharm.co.kr/eng), founded in 1957, is one of Korea's leading pharmaceutical companies with more than 500 employees and the largest production facilities in the country.


Catalent (www.catalent.com) is a leading provider of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 at 29 facilities worldwide and in fiscal 2010 generated more than $1.7 billion of annual revenue.

Adcock Ingram

Adcock Ingram (www.adcock.co.za), part of the Tiger Brands Group, is a leading South African pharmaceutical company with an 11.4% share of the private healthcare market. Adcock Ingram has an extensive range of prescription, generic, and over-the-counter products and also provides life saving hospital equipment and diagnostic products and services.

Shreya Life Sciences Pvt

Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in), a leading Indian-based pharmaceutical company. Shreya is the fourth largest distributor of insulin in the Indian insulin product market with a compound annual growth rate of 38% (per C MARC market research). Shreya has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments including cardiology, neuropathy, and diabetes. The company has business operations in India, Russia, the Commonwealth of Independent States, and African countries. The parties are making arrangements for the expansion of extant production facilities to meet the anticipated demand for the product in India and other jurisdictions where governmental approvals are pending.

Investor Relations

For more information please contact:
Todd Falls
Tel: 1-800-391-6755
Fax: (647) 547-7104
Email: tfalls@generex.com


OTC Bulletin Board

Listed Security

GNBT Common Stock

Transfer Agent

StockTrans, Inc.
44 West Lancaster Avenue
Ardmore, PA 19003
Phone 610-649-7300
Fax 610-649-7302

Corporate Counsel

Eckert Seamans Cherin & Mellott, LLC
1515 Market Street, 9th Floor
Philadelphia, PA 19102
Phone 215-851-8447
Fax 215-851-8383

All messages, including I-box content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. 
Please keep your posts on topic because your message(s) may be removed when:
► Posting content that's off-topic to the subject of this board;
► Posting statements that don't add value to the discussion; or
► When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp


High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#6277   Extremely Dangerous share structure. WINNER TAKES otced 10/16/18 09:41:03 PM
#6276   GNBT IS DONE!!!!! otced 10/16/18 09:00:50 PM
#6275   Any one know if the GNBT forum for kingman 10/15/18 03:40:42 PM
#6274   Not in this scam. I’m an in another Penny Monster 01 10/12/18 12:25:11 PM
#6273   Be very careful with GNBT they sell News. otced 10/12/18 12:22:59 PM
#6272   That’s some fantastic DD right there. Congrats Penny Monster 01 10/10/18 05:37:42 PM
#6271   Brooks, Houghton & Company, Inc. ("BHC") is a zino 10/04/18 11:19:45 AM
#6270   8-K Current Report to be filed on Tuesday, zino 10/04/18 10:52:34 AM
#6269   This part looks great too 1 mill OS: JA9791 10/04/18 10:44:35 AM
#6268   News Today! Dividends! fishhook 10/04/18 10:04:54 AM
#6267   Whats going on here with this one? WinningInvestments 08/12/18 04:10:19 PM
#6266   8k Today, Hmmm fishhook 07/09/18 06:10:43 PM
#6265   GNBT=Dogshit Itsjustmymoney 04/18/18 09:11:19 PM
#6264   News out. $GNBT confirms receipt of $700,000 from iidris 01/02/18 09:18:03 AM
#6263   I'm shocked, shocked I say. WeeZuhl 12/19/17 09:00:46 PM
#6262   LOI with CORE Tech WeeZuhl 08/31/17 04:35:02 PM
#6261   LOI with CORE Tech : http://www.otcmarkets.com/edgar/GetFilingHtml?Filing allezlOM 08/29/17 12:15:21 PM
#6260   Say wha? WeeZuhl 08/22/17 10:26:12 PM
#6259   First New Sickle Cell Drug to Launch in WeeZuhl 07/10/17 12:17:10 PM
#6258   Who or what woke up gnbt today stock smile86 07/10/17 10:57:23 AM
#6257   Hi Joe. GoClippers 06/01/17 08:44:07 PM
#6256   @ $0.02, I'll be a buyer...... Termite7 05/07/17 09:57:53 PM
#6255   Since yahoo keeps deleting this one (beside others) grobtekrebssvindl 05/03/17 10:49:06 PM
#6254   f this company, bunch of crooks slyguy8888 05/03/17 09:43:41 AM
#6253   "were all nuts" we all knew what is grobtekrebssvindl 04/28/17 11:12:40 PM
#6252   But someone said here thats all shareholders should ConArtists 04/27/17 11:41:35 PM
#6251   Looks like they cancel the whole thing,like always..no grobtekrebssvindl 04/27/17 08:57:58 PM
#6250   Thanks ice coffee 04/20/17 10:09:31 PM
#6249   "Wash. Rinse. Repeat." Pretty much grobtekrebssvindl 04/20/17 06:00:12 PM
#6248   I believe it is 7/7/17 tc2000chartreader 04/20/17 01:44:25 PM
#6247   Does anyone know what day in july gnbt ice coffee 04/20/17 11:21:28 AM
#6246   Wash. Rinse. Repeat. WeeZuhl 04/18/17 05:36:28 PM
#6245   I will be buying reduced shares when the Goku83 03/21/17 11:42:43 AM
#6244   Down 50 %,99% pumpers :) grobtekrebssvindl 03/20/17 02:20:16 PM
#6243   This was a bold move by the CEO: rjs9787 03/19/17 03:01:49 PM
#6241   Good synopsis of the way it was. DigitalTradz 03/19/17 12:00:43 PM
#6240   Simple synopsis: NuGenerex 03/19/17 10:43:08 AM
#6239   Complete nonsense. WeeZuhl 03/19/17 10:33:14 AM
#6238   I agree with Weezuhl, let's keep this a tc2000chartreader 03/19/17 10:06:59 AM
#6237   Gents or Ladies, please grow up. This is WeeZuhl 03/19/17 09:47:42 AM
#6236   1-1000 rs is not what it was are ConArtists 03/19/17 01:48:09 AM
#6235   Simple question, when the charts showed the downward DigitalTradz 03/18/17 08:38:50 PM
#6234   The 1-1000 reverse is smart. Without the reverse, tc2000chartreader 03/18/17 08:33:42 PM
#6233   As I said no it wasn't, your more ConArtists 03/18/17 08:01:54 PM
#6232   As I said, the RS was really a DigitalTradz 03/18/17 06:21:22 PM
#6231   I cannot remember much of any smart businees ConArtists 03/18/17 05:58:03 PM
#6230   If you think about the 1000:1 RS it DigitalTradz 03/18/17 05:35:11 PM
#6229   SO you say the tremendous if they get ConArtists 03/18/17 03:05:39 PM
#6228   To all you nay Sayers you can wine NuGenerex 03/18/17 02:32:57 PM
#6227   Well what needs labeling is what really are ConArtists 03/18/17 12:23:35 PM